16 / 2017-11-07 11:44:45

CLINICAL PHARMACOKINETICS OF PARECOXIB VIA INTRAVENOUS AND INTRAMUSCULAR INJECTIONS IN CHINESE POPULATIONS

Concentric Circular Antenna Array, Particle Swarm Optimization, Genetic Algorithm, Thinning, Side lobe Level

Objective: To study the clinical pharmacokinetics of parecoxib sodium via intravenous and intramuscular injections in Chinese populations. Methods: A total of 20 patients undergoing unilateral lower limb surgery were selected, and their related parameters were as follows: ASA: Grade I to II, age: 20 to 60 years, and weight: 50 to 80 kg. They were randomly assigned to two groups: the intravenous injection group (IV group) and the intramuscular injection group (IM group), with 10 patients in each group (N=10). Then, they were subjected to intravenous or intramuscular injection of parecoxib at 40mg (diluted with 2ml of normal saline) and venous blood sampling (2ml) at 0, 10, 20, 30, 40, 50, and 60min, and at 1.5, 2, 4, 6, 8, 12, 16, 20 and 24h after the injection. After that, the venous blood was added with heparin for anti-coagulation and centrifuged at 3000 rpm for 10min. The plasma was separated and placed in a refrigerator at -20 ℃. The plasma concentration of levobupivacaine was detected by means of high performance liquid chromatography (HPLC). All statistical analysis was performed using SPSS17.0 statistical software. Measurement data were expressed as mean±standard deviation ( ±s), and the t test and repeated measurement analysis of variance were adopted for inter- and intra-group comparisons. The count data were compared using theχ2 test, and P < 0.05 was considered statistically significant. Results After the intravenous and intramuscular injections of parecoxib, its plasma concentration was increased quickly, with its Cmax at 31.578±13.407 and 21.311±10.160mg·L-1, respectively. Then its plasma concentration was decreased rapidly, with no parecoxib detected in the plasma of all patients at 4h after its administration. Accordingly, the Cmax of valdecoxib in patients from the two groups was reached at 20min and 1.5h, respectively, with the values at 0.751±0.290 and 0.543±0.162mg·L-1, respectively, and no parecoxib was detected in the plasma of all patients at 24h after its administration. Processing by the pharmacokinetic software showed that the AUC of parecoxib of patients in Group II was higher than that in Group I (P<0.05) and that CL was lower than that in Group I (P <0.05), whereas the differences in the pharmacokinetic parameters of valdecoxib in patients between the two groups were not statistically significant (P>0.05). Conclusion The routes of administration can affect the clinical pharmacokinetic parameters of parecoxib, but not those of valdecoxib.